[The effectiveness of pioglitazone in the treatment of patients with coronary heart disease on the background of metabolic syndrome].
We investigated the effectiveness of pioglitazone in the treatment of patients with coronary heart disease in combination with MS. In the conduct of research revealed that the addition to standard therapy in patients with coronary heart disease on the background of metabolic syndrome pioglitazone led to a reliable slight decrease in body weight, BMI, hip circumference, waist their relationship. Receiving pioglitazone also significantly reduces the concentration of immunoreactive insulin and blood glucose levels, significantly altered lipid metabolism, which generally leads to a lower level of systemic inflammation, metabolism and reduces the severity of insulin resistance. This allows you to recommend the inclusion of pioglitazone in complex coronary heart disease and metabolic syndrome.